Drug Profile
Durlobactam/sulbactam - Entasis Therapeutics
Alternative Names: beta-lactam/ETX-2514; ETX 2514/Sulbactam; ETX-2514SUL; SUL-DUR; Sulbactam-durlobactam; Sulbactam/durlobactam; SULBACTUM/ETX-2514; XacduroLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Entasis Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Aza compounds; Carboxylic acids; Esters; Penicillins; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Nosocomial pneumonia; Ventilator associated pneumonia
- Preregistration Acinetobacter infections
- Phase II Pyelonephritis; Urinary tract infections
- No development reported Burkholderia infections
Most Recent Events
- 08 Mar 2024 Innoviva has an allowed patent for XACDURO® outside USA
- 28 Oct 2023 No recent reports of development identified for preclinical development in Burkholderia infections in USA
- 11 Oct 2023 Efficacy data from a phase III ATTACK trial in Acinetobacter infections presented at the IDWeek 2023 (IDW-2023)